* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Watson Pharmaceuticals

                   

Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH,...

yahoo.com
Sep 30, 2008 1 related
        

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented efficacy and safety data on silodosin, its investigational treatment for benign prostatic hyperplasia...

add comment

Watson Pharma: Prostate drug is effective, safe (AP)

yahoo.com
Sep 30, 2008
        

Monday September 29, 11:22 am ET Watson Pharma says Rapaflo reduced prostate enlargement symptoms, was well tolerated in trials CORONA, Calif. (AP) -- Watson Pharmaceuticals Inc. on Monday reported results from four late...

add comment

Depomed Announces Presentation of Clinical Data at the North American Menopause Society Annual...

yahoo.com
Sep 25, 2008
        

Thursday September 25, 4:05 pm ET MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (Nasdaq:DEPO - News ) today announced the presentation of data from its Phase 2 study of DM-5689 (formerly referred to as Gabapentin...

add comment
                   

Extended Look at an Extended-Release Drug (at Motley Fool)

yahoo.com
Sep 23, 2008
        

Negative publicity is something most companies should avoid. Teva Pharmaceutical's (Nasdaq: TEVA) generic version of GlaxoSmithKline's (NYSE: GSK) extended-release Wellbutrin is turning into an extended investigation....

add comment
                   

Ahead of the Bell: Generic drug makers (AP)

yahoo.com
Sep 23, 2008 2 related
        

Monday September 22, 9:18 am ET Analyst upgrades generic sector to 'Overweight,' raises ratings on Watson and Teva NEW YORK (AP) -- A Wachovia analyst upgraded the generic drug sector on Monday, and raised his ratings on...

add comment

Depomed to Present at the UBS Global Life Sciences Conference

redorbit.com
Sep 18, 2008 6 related
        

Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be...

add comment

Ahead of the Bell: Generic Drug Developers

ibtimes.com
Sep 16, 2008
        

NEW YORK - Shares of generic drug developer Watson Pharmaceuticals Inc. could be ready for a downturn, while rivals Teva Pharmaceutical Industries Ltd. and Mylan Inc. are in more stable positions, according to Goldman...

add comment

Premarket roundup: Utilities, WABCO Holdings

ibtimes.com
Sep 16, 2008 1 related
        

Among the premarket activity stories for Tuesday, Sept. 16, from AP Financial News: NEW YORK (AP)--Regulated utilities remain an attractive investment in a low-interest rate environment given expected net income growth of...

add comment

$21M settlement ironed out for drug cost lawsuit (AP)

yahoo.com
Sep 15, 2008
        

Thursday September 11, 2:51 pm ET $21M settlement may resolve class-action case alleging drug price inflation BOSTON (AP) -- Patients treated by a long list of mostly doctor-administered drugs over the past 17 years may...

add comment
                   

Xel Pharmaceuticals' Successful Completion Of Prototype Once-A-Week Huperzine A Transdermal Patch...

medicalnewstoday.com
Sep 12, 2008 2 related
        

Xel Pharmaceuticals, Inc. announced the completion of the development of its once-a-week Huperzine A transdermal patch for the treatment of Alzheimer's disease (AD). The prototype transdermal patch can deliver 400-800...

add comment